Because the antigen recognition domain of NHS76 is directed against areas of necrosis, and is therefore tumor targeted, we observed enhanced NHS-IL-12 retention in the TME, resulting in improved antitumor immunity, and increased infiltration of CD4+ and CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.